NEVIA Trademark

Trademark Overview


On Tuesday, May 13, 2025, a trademark application was filed for NEVIA with the United States Patent and Trademark Office. The USPTO has given the NEVIA trademark a serial number of 99183535. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Tuesday, May 13, 2025. This trademark is owned by Enteronova Medical Technologies Inc.. The NEVIA trademark is filed in the Computer & Software Products & Electrical & Scientific Products, Medical Instrument Products, and Medical & Beauty Services & Agricultural Services categories with the following description:

Downloadable mobile application software for providing and optimizing neuromodulation therapy for gut health; Software for managing gastrointestinal and inflammatory conditions through AI-guided transcutaneous cervical vagus nerve stimulation (tcVNS) and transcutaneous auricular vagus nerve stimulation (taVNS); Software for providing and tracking brain-gut axis treatment sessions, providing personalized gut health recommendations, monitoring progress, and interfacing with wearable medical devices.

Providing digital health services in the field of gastroenterology, namely, personalized therapeutic support and remote monitoring for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) through AI-guided neuromodulation therapy; Medical consultation and monitoring services using transcutaneous cervical and auricular vagus nerve stimulation delivered via wearable devices and mobile applications; Health services integrating bioelectronic therapy, symptom tracking, and real-time treatment adjustment to support immune modulation and inflammation reduction.

Non-invasive wearable medical devices for therapeutic neuromodulation, namely, devices that apply simultaneous transcutaneous cervical vagus nerve stimulation (tcVNS) and transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), Crohn’s Disease, and ulcerative colitis; Medical apparatus featuring dual-modality vagus nerve stimulation and AI-powered sensor feedback for modulating immune function and reducing gut inflammation.
nevia

General Information


Serial Number99183535
Word MarkNEVIA
Filing DateTuesday, May 13, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateTuesday, May 13, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesDownloadable mobile application software for providing and optimizing neuromodulation therapy for gut health; Software for managing gastrointestinal and inflammatory conditions through AI-guided transcutaneous cervical vagus nerve stimulation (tcVNS) and transcutaneous auricular vagus nerve stimulation (taVNS); Software for providing and tracking brain-gut axis treatment sessions, providing personalized gut health recommendations, monitoring progress, and interfacing with wearable medical devices.
Goods and ServicesProviding digital health services in the field of gastroenterology, namely, personalized therapeutic support and remote monitoring for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) through AI-guided neuromodulation therapy; Medical consultation and monitoring services using transcutaneous cervical and auricular vagus nerve stimulation delivered via wearable devices and mobile applications; Health services integrating bioelectronic therapy, symptom tracking, and real-time treatment adjustment to support immune modulation and inflammation reduction.
Goods and ServicesNon-invasive wearable medical devices for therapeutic neuromodulation, namely, devices that apply simultaneous transcutaneous cervical vagus nerve stimulation (tcVNS) and transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), Crohn’s Disease, and ulcerative colitis; Medical apparatus featuring dual-modality vagus nerve stimulation and AI-powered sensor feedback for modulating immune function and reducing gut inflammation.

Classification Information


International Class009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus.
US Class Codes021, 023, 026, 036, 038
Class Status Code6 - Active
Class Status DateTuesday, May 13, 2025
Primary Code009
First Use Anywhere DateTuesday, November 12, 2024
First Use In Commerce DateMonday, May 5, 2025

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateTuesday, May 13, 2025
Primary Code010
First Use Anywhere DateTuesday, November 12, 2024
First Use In Commerce DateMonday, May 5, 2025

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, May 13, 2025
Primary Code044
First Use Anywhere DateTuesday, November 12, 2024
First Use In Commerce DateMonday, May 5, 2025

Trademark Owner History


Party NameEnteronova Medical Technologies Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBellevue, WA 98004

Trademark Events


Event DateEvent Description
Tuesday, May 13, 2025NEW APPLICATION ENTERED
Tuesday, May 13, 2025APPLICATION FILING RECEIPT MAILED